Insights

If only Ellume was an ASX share! Why it’s making big news today

The private company Ellume is again in the ASX news today after announcing a lucrative deal with the US government for COVID-19 testing
The post If only Ellume was an ASX share! Why it’s making big news today appeared first on The Motley Fool Australia. –

Sonic Healthcare share price represented by man receiveing nasal swab from medical professional

For an unlisted company, Ellume certainly knows how to keep ASX investors talking. The Brisbane-based health company also made news last year. This was due to its announcement that the United States Food and Drug Administration (FDA) had endorsed one of its products.

As we discussed at the time, Ellume specialises in rapid diagnostic technology. The company had developed a rapid test for the COVID-19 infection. The test only costs around US$30. It can reportedly detect traces of coronavirus in as little as 15 minutes with a 94% sensitivity in detecting infection.

Following that endorsement from the FDA, Ellume ramped up plans to send more than 100,000 of its tests to the US. At the time, Ellume planned on delivering more than 5 million tests every month by March 2021. Ellume was (and remains) the first and only company that the FDA has licensed to produce ‘at-home’ COVID tests.

Ellume gets another green light from the USA

Today, Ellume has received more good news.

According to reporting in the Australian Financial Review (AFR) today, the Biden administration has inked a US$230 million deal with Ellume for increased testing. The report states that the White House is aiming for “mass production” and “slashed costs” with the deal.

It also sees it as a “critical way to reopen large parts of America’s battered economy”. Apparently, the Ellume test involves a nasal swab that is inserted into a cartridge and linked to a smartphone app. The White House is quoted in the AFR stating that this is a “chicken and egg problem that we have actually taken a step to solve today”.

Now Ellume has signed this deal, it will reportedly enable the company to build a US-based factory. The company is expecting to deliver 8.5 million COVID-19 testing kits. Until the factory is built, the company will deliver 100,000  tests a month from Australia.

This comes after the company told the AFR that it is on track to deliver roughly 200,000 tests per day “this quarter”. When the factory is completed and reaches full capacity, it will be able to produce as many as 19 million tests per month.

Ellume founder and CEO  Dr. Sean Parsons had this to say on the deal:

We are prioritising our partnership with the U.S. government to mobilise tests quickly and in the most impactful way… We will fulfill the order for these tests at the same time as we ramp up the output across our production facilities, creating more possibilities for retail and private institution use in the future.

Possible ASX flow-on effects

Even though Ellume is an unlisted company, its good fortune appears to be having some flow-on effects.

Shares of a blood-testing company Atomo Diagnostics Ltd (ASX: AT1) are up almost 2% today. Shares of another diagnostic testing manufacturer, Anteotech Ltd (ASX: ADO), are in a trading halt today “pending a further announcement”.

So stay tuned to this sector!

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post If only Ellume was an ASX share! Why it’s making big news today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!